Wenchao Guo

Wenchao Guo

Auto-generated profile, based on publicly available information

Wenchao Guo

DAMO Academy, Alibaba Group, Beijing, China; Hupan Laboratory, Hangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KCKai Cao
Kai Cao
YXYingda Xia
Yingda Xia
JYJiawen Yao
Jiawen Yao
XHXu Han
Xu Han
LLLukas Lambert
Lukas Lambert
JLJianping Lu
Jianping Lu
Pancreatic ductal adenocarcinoma (PDAC), the most deadly solid malignancy, is typically detected late and at an inoperable stage. Early or incidental detection is associated with prolonged survival, but screening asymptomatic individuals for PDAC using a single test remains unfeasible due to the low prevalence and potential harms of false positives. Non-contrast computed tomography (CT), routinely performed for clinical indications, offers the potential for large-scale screening, however, identification of PDAC using non-contrast CT has long been considered impossible. Here, we develop a deep learning approach, pancreatic cancer detection with artificial intelligence (PANDA), that can detect and classify pancreatic lesions with high accuracy via non-contrast CT. PANDA is trained on a dataset of 3,208 patients from a single center. PANDA achieves an area under the receiver operating characteristic curve (AUC) of 0.986–0.996 for lesion detection in a multicenter validation involving 6,239 patients across 10 centers, outperforms the mean radiologist performance by 34.1% in sensitivity and 6.3% in specificity for PDAC identification, and achieves a sensitivity of 92.9% and specificity of 99.9% for lesion detection in a real-world multi-scenario validation consisting of 20,530 consecutive patients. Notably, PANDA utilized with non-contrast CT shows non-inferiority to radiology reports (using contrast-enhanced CT) in the differentiation of common pancreatic lesion subtypes. PANDA could potentially serve as a new tool for large-scale pancreatic cancer screening.

24 June 2025 in Nature Medicine
Verified
Journal Article
Open access
CHCan Hu
Can Hu
YXYingda Xia
Yingda Xia
ZZZhilin Zheng
Zhilin Zheng
MCMengxuan Cao
Mengxuan Cao
GZGuoliang Zheng
Guoliang Zheng
XCXiangdong Cheng
Xiangdong Cheng
Early detection through screening is critical for reducing gastric cancer (GC) mortality. However, in most high-prevalence regions, large-scale screening remains challenging due to limited resources, low compliance and suboptimal detection rate of upper endoscopic screening. Therefore, there is an urgent need for more efficient screening protocols. Noncontrast computed tomography (CT), routinely performed for clinical purposes, presents a promising avenue for large-scale designed or opportunistic screening. Here we developed the Gastric Cancer Risk Assessment Procedure with Artificial Intelligence (GRAPE), leveraging noncontrast CT and deep learning to identify GC. Our study comprised three phases. First, we developed GRAPE using a cohort from 2 centers in China (3,470 GC and 3,250 non-GC cases) and validated its performance on an internal validation set (1,298 cases, area under curve = 0.970) and an independent external cohort from 16 centers (18,160 cases, area under curve = 0.927). Subgroup analysis showed that the detection rate of GRAPE increased with advancing T stage but was independent of tumor location. Next, we compared the interpretations of GRAPE with those of radiologists and assessed its potential in assisting diagnostic interpretation. Reader studies demonstrated that GRAPE significantly outperformed radiologists, improving sensitivity by 21.8% and specificity by 14.0%, particularly in early-stage GC. Finally, we evaluated GRAPE in real-world opportunistic screening using 78,593 consecutive noncontrast CT scans from a comprehensive cancer center and 2 independent regional hospitals. GRAPE identified persons at high risk with GC detection rates of 24.5% and 17.7% in 2 regional hospitals, with 23.2% and 26.8% of detected cases in T1/T2 stage. Additionally, GRAPE detected GC cases that radiologists had initially missed, enabling earlier diagnosis of GC during follow-up for other diseases. In conclusion, GRAPE demonstrates strong potential for large-scale GC screening, offering a feasible and effective approach for early detection. ClinicalTrials.gov registration: NCT06614179 .

20 August 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
YHYujian Hu
Yujian Hu
YXYilang Xiang
Yilang Xiang
YZYan-Jie Zhou
Yan-Jie Zhou
YHYangyan He
Yangyan He
DLDehai Lang
Dehai Lang
HZHongkun Zhang
Hongkun Zhang
The accurate and timely diagnosis of acute aortic syndrome (AAS) in patients presenting with acute chest pain remains a clinical challenge. Aortic computed tomography (CT) angiography is the imaging protocol of choice in patients with suspected AAS. However, due to economic and workflow constraints in China, the majority of suspected patients initially undergo noncontrast CT as the initial imaging testing, and CT angiography is reserved for those at higher risk. Although noncontrast CT can reveal specific signs indicative of AAS, its diagnostic efficacy when used alone has not been well characterized. Here we present an artificial intelligence-based warning system, iAorta, using noncontrast CT for AAS identification in China, which demonstrates remarkably high accuracy and provides clinicians with interpretable warnings. iAorta was evaluated through a comprehensive step-wise study. In the multicenter retrospective study (n = 20,750), iAorta achieved a mean area under the receiver operating curve of 0.958 (95% confidence interval 0.950–0.967). In the large-scale real-world study (n = 137,525), iAorta demonstrated consistently high performance across various noncontrast CT protocols, achieving a sensitivity of 0.913–0.942 and a specificity of 0.991–0.993. In the prospective comparative study (n = 13,846), iAorta demonstrated the capability to significantly shorten the time to correct diagnostic pathway for patients with initial false suspicion from an average of 219.7 (115–325) min to 61.6 (43–89) min. Furthermore, for the prospective pilot deployment that we conducted, iAorta correctly identified 21 out of 22 patients with AAS among 15,584 consecutive patients presenting with acute chest pain and under noncontrast CT protocol in the emergency department. For these 21 AAS-positive patients, the average time to diagnosis was 102.1 (75–133) min. Finally, iAorta may help prevent delayed or missed diagnoses of AAS in settings where noncontrast CT remains the only feasible initial imaging modality—such as in resource-limited regions or in patients who cannot receive, or did not receive, intravenous contrast.

7 March 2022 in Shock and Vibration
Verified
Journal Article
Open access
PDF file
BBBai Bo
Bai Bo
KYKuang Yu-Hua
Kuang Yu-Hua
WGWenchao Guo
Wenchao Guo
SMShimin Mao
Shimin Mao
Beveloid gears are usually employed to transfer motion of small shaft angle, but the assembly errors or misalignment can affect the gear tooth contact and dynamic performance. A dynamic model and tooth contact analysis model of the intersecting beveloid gear pair are established, the defects of the theoretical tooth surface in the meshing are analyzed, and a microgeometry modification method to improve the meshing performance is proposed. At the same time, the effects of system misalignment and manufacturing errors on its meshing characteristics are considered. By studying the sensitivity of the static and dynamic characteristics of beveloid gear on different misalignment components, the influence laws of misalignment on the contact pattern, transmission error, mesh stiffness, and dynamic excitation force are obtained, which give suggestions for tooth surface modification and support structural stiffness design of beveloid gear with a good NVH performance.

21 April 2026 in Annals of Oncology
Verified
Journal Article
Open access
XCX. Chen
X. Chen
MQM.Y. Qiu
M.Y. Qiu
JZJ.P. Zhang
J.P. Zhang
YXY.D. Xia
Y.D. Xia
KCK. Cao
K. Cao
ZLZaiyi Liu
Zaiyi Liu
Colorectal cancer (CRC) is a leading cause of cancer deaths, with early screening vital to reduce mortality. While methods like colonoscopy and CT colonography are available, they face challenges such as bowel prep, invasiveness, and low adherence. We aimed to develop COCA, a novel, non-invasive, cost-effective, and scalable method for CRC screening using non-contrast CT scans. This retrospective, multicenter, and international study included 1,321 CRC patients and 1,357 normal controls from two centers to develop COCA. We enhance the CRC detection capabilities of COCA by employing a joint lesion segmentation and classification architecture, optimized with mixed-supervised learning. For validation, we gathered abdominal and pelvic CT data from four external centers and chest CT data from four centers. A reader study involving 10 radiologists with varying levels of experience evaluated diagnostic performance on non-contrast CT first without COCA assistance and then with it. Additionally, we evaluated both the initial and iteratively improved versions of COCA in two real-world, multi-scenario cohorts comprising 27,433 consecutive patients. In a multicenter and international validation involving 2,053 patients across six centers, COCA demonstrated an area under the curve (AUC) ranging from 0.967 to 0.996 for CRC detection. COCA improved CRC detection sensitivity by 20.4% and specificity by 5.4% compared to radiologists. In the first real-world multi-scenario validation with 9,016 consecutive patients, COCA achieved a sensitivity of 88.2% and specificity of 99.5% for CRC detection. In the second external real-world validation involving 18,427 consecutive patients, COCA maintained a sensitivity of 86.6% and specificity of 99.8%, with a positive predictive value of 63.4%. COCA demonstrated robust performance across various clinical scenarios, including physical exams, emergency departments, outpatient, and inpatient settings, effectively preventing missed CRC diagnoses. These findings suggest that COCA could serve as a potential tool for large-scale opportunistic CRC screening.